FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 333:1495-1496 November 30, 1995 Number 22 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Osteoporosis is an increasing public health problem, and the costs related to hip fractures alone are expected to double in North America and Europe in the next 25 years. The disorder is characterized by enhanced bone fragility, resulting in an increased risk of fractures, and is usually defined according to the reduction in bone mineral density. Early diagnosis is now possible with the use of precise methods for measuring bone density. Optimal management consists of maximizing peak bone mass in early adulthood and preventing the rapid bone loss that occurs soon after the menopause in all women and again much . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Segal, E., Dvorkin, L., Lavy, A., Rozen, G. S., Yaniv, I., Raz, B., Tamir, A., Ish-Shalom, S. (2003). Bone Density in Axial and Appendicular Skeleton in Patients with Lactose Intolerance: Influence of Calcium Intake and Vitamin D Status. J. Am. Coll. Nutr. 22: 201-207 [Abstract] [Full Text]  
• Freedman, B., Weijer, C., Glass, K. C. (1996). Placebo Orthodoxy in Clinical Research I: Empirical and Methodological Myths. J Law Med Ethics 24: 243-251  
• (1996). ALENDRONATE FOR OSTEOPOROSIS. JWatch General 1996: 3-3 [Full Text]